Objective: Periodontitis is an infectious disease leading to inflammation and destruction of tissue surrounding and supporting the tooth. The progress of the inflammatory response depends on the host’s immune system and risk factors such as stress. The aim of the present study was to investigate the role of the endocannabinoid anandamide (AEA) in experimental periodontitis with restraint stress, since the endocannabinoid system is known to modulate the hypothalamo-pituitary-adrenal axis as well as immune functions and has been found in human gingival tissues. Methods: Experimental periodontitis was induced by ligature around first inferior molars and immobilization stress for 2 h twice daily for 7 days in a rat model. Results: Corticosterone plasma levels, locomotor activity, adrenal gland weight and bone loss were increased in periodontitis and stress groups, and there was also less weight gain. The inflammatory parameters such as prostaglandin E2 (radioimmunoassay), nitric oxide (radioconversion of 14C-arginine), tumor necrosis factor (TNF)-α (ELISA) and interleukin (IL)-1β (Western blot) measured in the gingival tissue were significantly increased in the periodontitis groups compared to the control group. Local injection of AEA (10–8M, 30 µl) decreased corticosterone plasma levels and the content of the cytokines TNF-α and IL-1β in gingival tissue in periodontitis-stress groups. These AEA-induced inhibitions were mediated by CB1 and CB2 cannabinoid receptors since the injection of both antagonists together, AM251 (10–6M) and AM630 (10–6M) in 30 µl, prevented these effects. Conclusion: The endocannabinoid AEA diminishes the inflammatory response in periodontitis even during a stressful situation.

1.
Haffajee AD, Socransky SS: Microbial etiological agents of destructive periodontal diseases. Periodontol 2000 1994;5:78–111.
2.
Dye BA: Global periodontal disease epidemiology. Periodontol 2000 2012;58:10–25.
3.
Romanelli H, Gonzalez y Rivas M, Chiappe V, Gómez M, Macchi R: Periodontal treatment needs in Argentine adult subjects. Acta Odontol Latinoam 2007;20:39–47.
4.
Stashenko P, Jandinski JJ, Fujiyoshi P, Rynar J, Socransky SS: Tissue levels of bone resorptive cytokines in periodontal disease. J Periodontol 1991;62:504–509.
5.
Koide M, Kinugawa S, Takahashi N, Udagawa N: Osteoclastic bone resorption induced by innate immune responses. Periodontol 2000 2010;54:235–246.
6.
Berglundh T, Donati M: Aspects of adaptive host response in periodontitis. J Clin Periodontol 2005;32(suppl 6):87–107.
7.
Genco RJ: Current view of risk factors for periodontal diseases. J Periodontol 1996;67:1041–1049.
8.
Breivik T, Thrane PS, Murison R, Gjermo P: Emotional stress effects on immunity, gingivitis and periodontitis. Eur J Oral Sci 1996;104:327–334.
9.
Genco RJ, Ho AW, Grossi SG, Dunford RG, Tedesco LA: Relationship of stress, distress, and inadequate coping behaviors to periodontal disease. J Periodontol 1999;70:711–723.
10.
Boyapati L, Wang HL: The role of stress in periodontal disease and wound healing. Periodontol 2000 2007;44:195–210.
11.
Gaspersic R, Stiblar-Martincic D, Skaleric U: Influence of restraint stress on ligature-induced periodontitis in rats. Eur J Oral Sci 2002;110:125–129.
12.
Struillou X, Boutigny H, Soueidan A, Layrolle P: Experimental animal models in periodontology: a review. Open Dent J 2010;4:37–47.
13.
Di Paola R, Mazzon E, Muià C, Crisafulli C, Terrana D, Greco S, Britti D, Santori D, Oteri G, Cordasco G, Cuzzocrea S: Effects of etanercept, a tumour necrosis factor-alpha antagonist, in an experimental model of periodontitis in rats. Br J Pharmacol 2007;150:286–297.
14.
Verzeletti GN, Gaio EJ, Rösing CK: Effect of methotrexate on alveolar bone loss in experimental periodontitis in Wistar rats. Acta Odontol Scand 2007;65:348–351.
15.
Uğar-Cankal D, Ozmeric N: A multifaceted molecule, nitric oxide in oral and periodontal diseases. Clin Chim Acta 2006;366:90–100.
16.
Queiroz-Junior CMF, Pacheco CM, Maltos KLM, Caliari MV, Duarte IDG, Francischi JN: Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats. J Periodontal Res 2009;44:153–160.
17.
Howlet AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ: Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004;47:345–358.
18.
Weidenfeld J, Feldman S, Mechulam R: Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 1994;59:110–112.
19.
Wenger T, Jamali KA, Juaneda C, Leonardelli J, Tramu G: Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem Biophys Res Commun 1997;237:724–728.
20.
Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ: Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004;145:5431–5438.
21.
Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P: Endocannabinoids and immune regulation. Pharmacol Res 2009;60:85–92.
22.
Prestifilippo JP, Fernández-Solari J, de la Cal C, Iribarne M, Suburo AM, Rettori V, McCann SM, Elverdin JC: Inhibition of salivary secretion by activation of cannabinoid receptors. Exp Biol Med (Maywood) 2006;231:1421–1429.
23.
Nakajima Y, Furuichi Y, Biswas KK, Hashiguchi T, Kawahara K, Yamaji K, Uchimura T, Izumi Y, Maruyama I: Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-ĸB pathway inhibition. FEBS Lett 2006;580:613–619.
24.
Kozono S, Matsumaya T, Bisawa KK, Kawahara K, Nakajima Y, Yoshimoto T, Yonamine Y, Kadomatsu H, Tancharoen S, Hashiguchi T, Noguchi K, Maruyama I: Involvement of the endocannabinoid system in periodontal healing. Biochem Biophys Res Commun 2010;394:928–933.
25.
Prut L, Belzung C: The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003;463:3–33.
26.
Faletti A, Perez Martinez S, Perotti C, de Gimeno MA: Activity of ovarian nitric oxide synthase (NOS) during ovulatory process in the rat: relationship with prostaglandins (PGs) production. Nitric Oxide 1999;3:340–347.
27.
Bredt DS, Snyder SH: Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990;87:682–685.
28.
Sallay K, Sanavi F, Ring I, Pham P, Behling UH, Nowotny A: Alveolar bone destruction in the immunosuppressed rat. J Periodontal Res 1982;17:263–274.
29.
De Laurentiis A, Fernandez-Solari J, Mohn C, Burdet B, Zorrilla Zubilete MA, Rettori V: The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. J Neuroimmunol 2010;221:32–41.
30.
Xie R, Kuijpers-Jagtman AM, Maltha JC: Inflammatory responses in two commonly used rat models for experimental tooth movement: comparison with ligature-induced periodontitis. Arch Oral Biol 2011;56:159–167.
31.
Kuhr A, Popa-Wagner A, Schmoll H, Schwahn C, Kocher T: Observations on experimental marginal periodontitis in rats. J Periodontal Res 2004;39:101–106.
32.
Klausen B: Microbiological and immunological aspects of experimental periodontal disease in rats: a review article. J Periodontol 1991;62:59–73.
33.
Breivik T, Sluyter F, Hof M, Cools A: Differential susceptibility to periodontitis in genetically selected Wistar rat lines that differ in their behavioral and endocrinological response to stressors. Behav Genet 2000;30:123–130.
34.
Kinane DF, Preshaw PM, Loos BG: Host-response: understanding the cellular and molecular mechanisms of host-microbial interactions – consensus of the Seventh European Workshop on Periodontology. J Clin Periodontol 2011;38(suppl 11):44–48.
35.
Breivik T, Gundersen Y, Myhrer T, Fonnum F, Osmundsen H, Murison R, Gjermo P, von Hörsten S, Opstad PK: Enhanced susceptibility to periodontitis in an animal model of depression: reversed by chronic treatment with the anti-depressant tianeptine. J Clin Periodontol 2006;33:469–477.
36.
O’Connor TM, O’Halloran DJ, Shanahan F: The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia. QJM 2000;93:323–333.
37.
Romeo HE, Tio DL, Rahman SU, Chiappelli F, Taylor AN: The glossopharyngeal nerve as a novel pathway in immune-to-brain communication: relevance to neuroimmune surveillance of the oral cavity. J Neuroimmunol 2001;115:91–100.
38.
Besedovsky HO, del Rey A: Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996;17:64–102.
39.
Györfi A, Fazekas A, Rosivall L: Neurogenic inflammation and the oral mucosa. J Clin Periodontol 1992;19:731–736.
40.
Pradeep AR, Raj S, Aruna G, Chowdhry S: Gingival crevicular fluid and plasma levels of neuropeptide substance-P in periodontal health, disease and after nonsurgical therapy. J Periodontal Res 2009;44:232–237.
41.
Larsen PJ, Jessop D, Patel H, Lightman SL, Chowdrey HS: Substance P inhibits the release of anterior pituitary adrenocorticotrophin via a central mechanism involving corticotrophin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus. J Neuroendocrinol 1993;5:99–105.
42.
McEwen BS: Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol 2008;583:174–185.
43.
Ziegler CG, Mohn C, Lamounier-Zepter V, Rettori V, Bornstein SR, Krug AW, Ehrhart-Bornstein M: Expression and function of endocannabinoid receptors in the human adrenal cortex. Horm Metab Res 2010;42:88–92.
44.
Napimoga MH, Benatti BB, Lima FO, Alves PM, Campos AC, Pena-Dos-Santos DR, Severino FP, Cunha FQ, Guimarães FS: Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. Int Immunopharmacol 2009;9:216–222.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.